| Dr Vincent Ulysses Rapini Jr, DDS | |
|
2800 College Ave, Alton, IL 62002-4700 | |
| (618) 474-7047 | |
| Not Available |
| Full Name | Dr Vincent Ulysses Rapini Jr |
|---|---|
| Gender | Male |
| Speciality | Dentist |
| Location | 2800 College Ave, Alton, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144550815 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 019.022428 (Illinois) | Secondary |
| 122300000X | Dentist | 019022428 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vincent Ulysses Rapini Jr, DDS 2800 College Ave, Alton, IL 62002-4700 Ph: (618) 474-7047 | Dr Vincent Ulysses Rapini Jr, DDS 2800 College Ave, Alton, IL 62002-4700 Ph: (618) 474-7047 |
News Archive
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
A new gonorrhea treatment, based on an anti-cancer therapy developed by a Buffalo startup company, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published today by University at Buffalo scientists in the Journal of Infectious Diseases.
A multidisciplinary team led by researchers at the University of California, San Diego has determined the structure of a protein found in cells that shows potential as a target for the development of new drugs to treat diabetes.
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
› Verified 9 days ago
Jessica Chellis, Dentist Medicare: Not Enrolled in Medicare Practice Location: 2800 College Ave, Alton, IL 62002 Phone: 618-474-7000 | |
Dr. Sandra Kay Highsmith, D.M.D. Dentist Medicare: Not Enrolled in Medicare Practice Location: 2800 College Ave, Alton, IL 62002 Phone: 618-474-7208 | |
Dr. Lucas Winebaugh, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 2800 College Ave, Alton, IL 62002 Phone: 618-474-7000 | |
Dr. Adam Kennedy Remm, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 2800 College Ave, Alton, IL 62002 Phone: 618-474-7000 | |
Prof. Martin F. Land, DDS, MSD Dentist Medicare: Not Enrolled in Medicare Practice Location: 2800 College Ave - Bldg. 263, Southern Illinois University, School Of Dental Medicine, Alton, IL 62002 Phone: 618-474-7072 Fax: 618-474-7141 | |
Dr. Patrick William Malone, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 2800 College Ave, Alton, IL 62002 Phone: 630-391-8330 | |
Dr. Alexandria Nicole Wold, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 2800 College Ave, Alton, IL 62002 Phone: 618-474-7164 |